Ferring Launches Rebyota for the Prevention of Recurrence of C. diff Infection in Adults in the US
Shots:
- The company reported the commercial availability of the first microbiome-based treatment Rebyota in the US to prevent the recurrence of C. diff inf. in individuals aged ≥18yrs.
- The P-III trial (PUNCH CD3) trial evaluates Rebyota in 262 patients which showed a superiority over PBO, Bayesian model-estimated treatment success rate (70.6% vs 57.5%) @8wks. with a 99.1% posterior probability, ≥90% of study patients remained free of recurrent C. diff inf. through 6mos, who achieved treatment success, the incidence of TEAEs (55.6% vs 44.8%)
- The company is committed to making Rebyota accessible to patients & healthcare providers & REBYOTA CONNECT program offers guidance to healthcare providers. The company also offers co-pay & patient assistance programs
Ref: Businesswire | Image: Ferring
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
